Biopreservation Market Report Global Forecast By Product, Application, Countries and Company Analysis (2026-2034)

Biopreservation Market Size and Forecast 2026-2034

Biopreservation Market is expected to reach US$ 22.76 billion by 2034 from US$ 9.62 billion in 2025, with a CAGR of 10.04% from 2026 to 2034. Rising demand for regenerative medicine, stem cell therapies, and personalized medicine significantly drives the biopreservation market. Expanding biobanking activities, increasing R&D investments in cell-based research, and growing adoption of advanced preservation technologies further accelerate market growth across healthcare, biotechnology, and pharmaceutical sectors.

Biopreservation Industry Overview

Biopreservation refers to the process of maintaining the integrity, viability, and functionality of biological samples over time using controlled storage and preservation methods. These samples can include cells, tissues, organs, DNA, vaccines, and other biologics used in research and clinical applications. Techniques such as cryopreservation, vitrification, hypothermic storage, and freeze-drying enable long-term storage without damaging biological structures. Biopreservation is essential for biobanking, regenerative medicine, cell therapy manufacturing, and drug discovery. It supports global healthcare and scientific advancements by ensuring high-quality biological materials remain usable for diagnostics, therapeutic development, and research.

The biopreservation market is driven by growing adoption of regenerative medicine, rapid expansion of biobanking, and increasing demand for cell- and gene-based therapies. Rising prevalence of chronic diseases promotes the need for preserved biological samples for diagnostics and treatment development. Advances in cryopreservation equipment, cold-chain logistics, and preservation media improve storage efficiency and reliability. Pharmaceutical and biotechnology companies are investing heavily in R&D involving stem cells, immunotherapies, and precision medicine, increasing the need for long-term sample preservation. Government funding for biomedical research and the commercialization of cell therapies further support sustained market growth worldwide.

Growth Drivers for the Biopreservation Market

Expansion of Regenerative Medicine and Cell Therapy

The rapid growth of regenerative medicine, including stem cell therapy, gene therapy, and tissue engineering, is a major driver for the biopreservation market. These therapies rely heavily on the availability of viable, high-quality cells and tissues that must be preserved under highly controlled conditions. As the number of clinical trials and approved therapies increases, so does the demand for advanced preservation technologies and cryogenic storage solutions. Biopreservation ensures that biological materials remain intact from research through clinical application. Additionally, the global rise in chronic diseases-such as cancer, diabetes, and cardiovascular disorders-boosts the need for regenerative treatments. Government initiatives, academic research, and biotechnology investments are further expanding infrastructure for cell-based science, directly increasing the need for robust biopreservation systems.

Growth of Biobanking and Precision Medicine

Biobanking has become essential for modern biomedical research, enabling long-term storage of biological samples used to study diseases, drug responses, and genetic variations. The expansion of population-based biobanks and personalized medicine programs has significantly fueled demand for reliable preservation technologies. As healthcare shifts toward individualized treatment strategies, researchers require extensive, high-quality sample libraries, including blood, tissues, stem cells, and DNA. Biopreservation systems ensure sample viability and consistency, which is critical for generating accurate clinical and genomic insights. The integration of digital technologies, automated storage systems, and AI-powered data management further enhances biobanking efficiency. Public-private partnerships, government funding, and pharmaceutical collaborations continue to broaden the scale and sophistication of worldwide biobanking initiatives.

Technological Advancements in Preservation and Storage Solutions

Technological innovation remains a major catalyst for biopreservation market growth, with continual improvements in cryogenic storage, preservation media, and automated monitoring systems. Advances in non-toxic cryoprotectants, vitrification methods, and controlled-rate freezing enhance cell viability and reduce damage during freezing and thawing. A notable milestone occurred in March 2025, when Teknova and Pluristyx introduced PluriFreeze(TM), an integrated cryopreservation system designed to improve cell-therapy viability and shorten development timelines. This solution streamlines freezing workflows and offers higher post-thaw recovery, supporting the efficiency of cell and gene therapy manufacturing. Meanwhile, innovations in ultra-low-temperature freezers, smart sensor technologies, and automated storage platforms strengthen reliability and regulatory compliance. These advancements are crucial for applications in stem cell banking, biologics manufacturing, vaccine development, and precision medicine. As demand for high-quality biological materials rises, cutting-edge preservation systems continue to accelerate adoption across clinical and research environments.

Challenges in the Biopreservation Market

High Cost of Equipment and Storage Infrastructure

One of the main challenges limiting the biopreservation market is the high cost associated with advanced preservation equipment, cryogenic freezers, and specialized storage facilities. Implementing high-quality cold-chain logistics and controlled-rate freezing systems requires substantial initial investment, making adoption difficult for smaller laboratories and developing regions. Additionally, the continuous operating costs for energy-intensive freezers, liquid nitrogen supply, and facility maintenance add financial pressure. Regulatory compliance and validation processes further increase expenses. As biobanking and cell therapy manufacturing expand, the challenge of maintaining scalable, cost-efficient, and reliable preservation infrastructure remains a barrier for wider global adoption.

Stringent Regulatory Requirements and Quality Control

Biopreservation involves storing biological materials intended for research, diagnostics, and therapeutic use, making regulatory compliance essential but challenging. Strict guidelines govern sample handling, storage conditions, cryoprotectant usage, and equipment performance. Meeting these standards requires significant documentation, validation, and quality assurance processes. Any deviation can compromise sample viability, leading to clinical setbacks or research inaccuracies. Additionally, global variations in regulatory frameworks create complexity for multinational biobanks and therapy developers. Maintaining uniform quality across diverse facilities is difficult, especially as sample volumes increase. These regulatory demands can slow market expansion by requiring extensive resources, specialized expertise, and continuous monitoring.

United States Biopreservation Market

The United States is one of the largest and most advanced biopreservation markets, driven by strong biotechnology, pharmaceutical, and healthcare sectors. Extensive investment in regenerative medicine, cell and gene therapy, and precision medicine fuels demand for high-quality preservation technologies. The country hosts numerous biobanks, research institutions, and cell therapy manufacturers that require reliable cryogenic storage and preservation solutions. Supportive government funding, robust clinical trial activity, and the presence of leading industry players accelerate innovation. Additionally, the U.S. has well-established regulatory frameworks and advanced logistics infrastructure, enabling efficient cold-chain management. The growing prevalence of chronic diseases further increases the need for preserved biological samples across research and clinical applications.

Germany Biopreservation Market

Germany represents a strong biopreservation market in Europe, supported by its advanced biomedical research infrastructure and strong biotechnology ecosystem. The country invests heavily in stem cell research, personalized medicine, and biobanking initiatives, increasing the need for high-quality preservation systems. German research institutes and pharmaceutical companies frequently collaborate on developing innovative cell-based therapies, creating consistent demand for cryogenic equipment and preservation media. The country's strict regulatory standards drive the adoption of technologically advanced and compliant storage solutions. Additionally, Germany's leadership in engineering and precision manufacturing supports innovation in ultra-low-temperature freezers and monitoring systems. Growing healthcare needs and ongoing R&D programs make Germany a key contributor to the European biopreservation landscape.

China Biopreservation Market

China's biopreservation market is expanding rapidly due to strong government investment in biotechnology, regenerative medicine, and biobanking infrastructure. The country is witnessing growth in stem cell research, gene therapy development, and large-scale population health studies, all of which require advanced preservation solutions. China's increasing number of biopharmaceutical companies and clinical research organizations drives demand for cryogenic freezers, preservation media, and automated storage systems. Government-led health initiatives, such as precision medicine programs, further strengthen the market. Although regulatory frameworks continue to evolve, the country is making substantial progress in quality standards and research capabilities. Rapid urbanization, rising disease burden, and growing healthcare expenditure contribute to long-term market growth.

Saudi Arabia Biopreservation Market

Saudi Arabia's biopreservation market is growing as the country expands its biotechnology and healthcare sectors under Vision 2030. Investments in medical research, stem cell programs, and advanced diagnostics are creating greater demand for preservation technologies. The establishment of new research centers, biobanks, and academic institutions drives market adoption of cryogenic storage and preservation media. Increasing focus on personalized medicine and genetic research also supports growth. While the market is smaller compared to Western regions, infrastructure development and government support are accelerating modernization. Challenges include reliance on imported equipment and the need for specialized technical expertise. Nonetheless, Saudi Arabia's long-term health initiatives position the biopreservation sector for steady expansion.

Recent Developments in Biopreservation Market

• In May 2025, Azenta Inc. announced a strategic partnership with Form Bio to develop an integrated sequencing and AI-powered data analysis platform aimed at accelerating AAV gene therapy development.
• In March 2025, Johnson & Johnson revealed plans to invest more than USD 55 billion in its U.S. operations over the next four years, including new manufacturing facilities that will require advanced biopreservation technologies.
• In February 2025, Thermo Fisher Scientific introduced the Krios 5 Cryo-TEM, a next-generation cryo-electron microscopy platform featuring AI-driven automation to enable atomic-resolution imaging and advance structural biology research.
• In January 2025, Azenta Inc. was selected by the UK Biocentre to implement its BioArc Ultra high-density automated storage system, expanding the facility's sample capacity by approximately 16 million.
• In June 2023, BioLife Solutions, Inc. launched a new large-capacity controlled-rate freezer (CRF) to expand its product line, supporting both autologous and allogeneic cell and gene therapy manufacturing and enabling high-volume cell therapy processing.
• In January 2023, Thermo Fisher Scientific completed its acquisition of The Binding Site Group, a global leader in specialty diagnostics, strengthening its portfolio with advanced technologies for diagnosing and monitoring multiple myeloma.

Market Segmentation

Product

• Equipment
• Media
• Laboratory Information Management System (LIMS)

Application

• Regenerative Medicine
• Biobanking
• Drug Discovery

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All the key players have been covered from 5 Viewpoints:

• Business Overview
• Key Persons
• Recent Development & Strategies
• SWOT Analysis
• Financial Insights

Key Players Analysis:

• Thermo Fisher Scientific Inc.
• Cryport, Inc.
• Eppendorf AG
• BioLife Solutions Inc
• Azenta Inc
• Merck KGaA
• Qiagen NV
• Chart Industries, Inc.